With news that the Japanese whiskey and beer giant Suntory Holdings has agreed to purchase the maker of the legendary Jim Beam bourbon for $13.6 billion, another chunk of Americana falls into foreign hands. But, in this case, perhaps, ably so.
Suntory ��which makes Yamazaki whiskey and Premium Malt's beer ��totally gets American shtick. It was, after all, among the earliest major Asian marketers to cozy-up to American celebrities to sell stuff in Japan. Way back in the "Rat Pack" heyday of the early 1970s, no less than Sammy Davis Jr., showed up in ads for Suntory brands in Japan.
Even folks who don't have the name Suntory at the tips of their tongues, probably are familiar with actor Bill Murray, whose character in the 2003 film Lost in Translation, so perfectly depicted the image of a fading American actor seeking redemption �� and a few bucks �� overseas. His most famous line from the film: "For relaxing times, make it Suntory time."
Best Growth Companies To Invest In Right Now: Navidea Biopharmaceuticals Inc (NAVB)
Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, incorporated in 1983, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�� radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�� disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.
Lymphoseek
Navidea�� pipeline includes clinical-stage radiopharmaceutical agents used to identify the presence and status of disease. Lymphoseek (Kit for the Preparation of Technetium Tc99m for Injection) is a lymph node targeting agent intended for use in intraoperative lymphatic mapping (ILM) procedures and lymphoscintigraphy employed in the overall diagnostic assessment of certain solid tumor cancers. The lymph system is a component of the body�� immune system. The key components of the lymph system are lymph nodes-small anatomic structures that contain disease-fighting lymphocytes, filter lymph of bacteria and cancer cells, and signal infection in response to heightened levels of pathogens. In Navidea�� Phase III clinical studies of Lymphoseek, it detected over 99% of positive nodes identified by vital blue dye (VBD). As of December 31, 2011, Navidea, in co-operation with UC, San Diego affiliate (UCSD), completed or initiated five Phase I clinical trials, one multi-center Phase II trial and three multi-center Phase II trials inv! olving Lymphoseek. Two Phase III studies were completed in subjects with breast cancer and melanoma. During the year ended December 31, 2011, data from NEO3-09 were released, which indicated that all primary and secondary endpoints for the study were met. As of December 31, 2011, third Phase III clinical trial for Lymphoseek in subjects with head and neck squamous cell carcinoma (NEO3-06) was in progress.
AZD4694
AZD4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as Alzheimer's disease (AD). It binds to beta-amyloid deposits in the brain that can then be imaged in positron emission tomography (PET) scans. Amyloid plaque pathology is a required feature of AD and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 has been studied in several clinical trials. Clinical studies through Phase IIa have included more than 80 patients to date, both suspected AD patients and healthy volunteers. No significant adverse events have been observed. Results suggest that AZD4694 has the ability to image patients quickly and safely with high sensitivity.
RadioImmunoGuided Surgery
As of December 31, 2011, RIGScan had been studied in a number of clinical trials, including Phase III studies. Navidea has conducted two Phase III studies, NEO2-13 and NEO2-14, of RIGScan in patients with primary and metastatic colorectal cancer, respectively. Both studies were multi-institutional involving cancer treatment institutions in the United States, Israel, and the European Union.
The Company competes with Pharmalucence, Eli Lilly, Bayer Schering, General Electric and GE Healthcare.
Advisors' Opinion:- [By Lauren Pollock]
Navidea Biopharmaceuticals Inc.(NAVB) said the U.S. Food and Drug Administration has granted a priority review for an expanded use of its Lymphoseek drug for some patients with head and neck cancer. Shares dropped 5.4% to $1.97 premarket.
- [By Keith Speights]
3. Navidea Biopharmaceuticals (NYSEMKT: NAVB )
Some investors were likely befuddled by Navidea's stock action earlier this year. The company received FDA approval in March for Lymphoseek, its radiopharmaceutical agent used for imaging lymph nodes in patients with breast cancer or melanoma. That was great news, but shares dropped quickly and still haven't returned to previous levels. - [By Sean Williams]
Another prime example here would be Navidea Biopharmaceuticals' (NYSEMKT: NAVB ) Lymphoseek which is an injectable agent used in external lymph-node imaging and intra-operative lymphatic mapping. In English this means it will dramatically improve the staging and treatment options for patients with breast cancer. Being that breast cancer was also listed as a commonly misdiagnosed cancer, this is a big step in the right direction for patient care.
- [By Sean Williams]
Diagnostics can also play an important role in early and late-stage breast cancer diagnoses. Navidea Biopharmaceuticals (NYSEMKT: NAVB ) had Lymphoseek, its external lymph-node imaging and intra-operative lymphatic mapping diagnostic device, approved by the Food and Drug Administration earlier this year to help doctors stage cancer. Discovering whether breast cancer has invaded adjacent lymph nodes has never been easier or safer thanks to Lymphoseek, and it can dramatically aid physicians in determining the best course of action for breast cancer patients.
Top Japanese Stocks To Invest In Right Now: Dollar/Yen (YY)
YY Inc., through its subsidiaries, operates an online social platform in the People�s Republic of China. It provides YY Client, a personal computer based user software that offers real-time access to user-created online social activities groups. The company also offers Web-based YY that enables users to conduct real-time interactions on the Web without any downloads or installations; and Mobile YY, a smartphone application. In addition, it operates Duowan.com, a game media Website that provides information on online games and other resources for users and online game players. The company was founded in 2005 and is based in Guangzhou, the People�s Republic of China.
Advisors' Opinion:- [By Michael Cintolo]
This has created huge opportunities for companies like YY Inc. (YY), the wildly popular Chinese online social platform that's still evolving.
The core of YY's appeal is software that allows users to interact online in real time without any downloads or installations.
- [By Monica Gerson]
YY (NASDAQ: YY) shares dropped 1.89% to $79.95 in pre-market trading after the company announced a proposed offering of $400 million convertible senior notes.
- [By Jeremy Bowman]
What: Shares of Chinese stocks were getting dumped today following the Shanghai Composite's 5.3% plunge last night. Among those feeling the pain were YY (NASDAQ: YY ) , Dangdang (NYSE: DANG ) , Trina Solar (NYSE: TSL ) , Giant Interactive (NYSE: GA ) , and LDK Solar (NYSE: LDK ) , all of which were down by 10% or more at one point today.
Top Japanese Stocks To Invest In Right Now: Johnson Controls Inc.(JCI)
Johnson Controls, Inc. engages in building efficiency, automotive experience, and power solutions businesses worldwide. Its building efficiency business designs, produces, markets, and installs integrated heating, ventilating, and air conditioning systems, as well as building management systems, controls, and security and mechanical equipment. This business also provides technical services, energy management consulting, and operations of real estate portfolios for the non-residential buildings market. In addition, this business offers residential air conditioning and heating systems, and industrial refrigeration products. The company?s automotive experience business designs and manufactures interior products and systems for passenger cars and light trucks, including vans, pick-up trucks, and sport/crossover utility vehicles. It offers seating systems and components; cockpit systems comprising instrument panels and clusters, information displays, and body controllers; overh ead systems, such as headliners and electronic convenience features; floor consoles; and door systems. This business also produces automotive interior systems for original equipment manufacturers. Its power solutions business produces lead-acid automotive batteries serving automotive original equipment manufacturers and the general vehicle battery aftermarket. This business produces lead-acid batteries, as well as offers absorbent glass mat and lithium-ion battery technologies to power hybrid vehicles. The company was formerly known as Johnson Electric Service Company and changed its name to Johnson Controls, Inc. in 1974. Johnson Controls, Inc. was founded in 1885 and is headquartered in Milwaukee, Wisconsin.
Advisors' Opinion:- [By Ben Levisohn]
Johnson Controls�(JCI) has dropped 3% to $41.26 after it was downgraded to Underweight from Overweight.
Achillion Pharmaceuticals (ACHN) has plunged 51% to $3.53 after the FDA kept a hold on its hepatitis C drug in trials. The stock was downgraded to Underperform from Neutral at Merrill Lynch.
- [By Marc Bastow]
Automatic temperature control device manufacturer Johnson Controls (JCI) raised its quarterly dividend 16% to 22 cents per share, payable on Jan. 6 to shareholders of record as of Dec. 16.
JCI Dividend Yield: 1.75% - [By Luke Jacobi]
Johnson Controls (NYSE: JCI) closed down 2.42 percent to $41.50. Analysts at Morgan Stanley downgraded the stock from Overweight to Underweight.
Global Markets
- [By Ian Sayson]
The benchmark index in Colombo, Sri Lanka, was the only major Asia-Pacific measure to advance today, by less than 0.1 percent. Jakarta�� Composite Index (JCI) retreated 3.7 percent, Thailand�� SET Index slumped 2.5 percent and the S&P BSE India Index slid 2.7 percent.
Top Japanese Stocks To Invest In Right Now: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Genomic Health (NASDAQ: GHDX ) , a provider of genome-based clinical diagnostic tests, popped as much as 10% following the release of its first-quarter results.
- [By John Udovich]
Small cap genomics stocks Rosetta Genomics Ltd (NASDAQ: ROSG), Genomic Health, Inc (NASDAQ: GHDX) and CollabRx Inc (NASDAQ: CLRX) are at the forefront of genomics testing�or research. I should mention that Wikipedia defines genomics�as a�discipline in genetics that applies recombinant DNA, DNA sequencing methods and bioinformatics to sequence, assemble and analyze the function and structure of genomes (the complete set of DNA within a single cell of an organism). A 2013 Booz Allen Hamilton report on the sector noted that in�2011, the US genetic and genomic clinical testing market size was estimated to be $5.9 billion while the�number of available tests has grown substantially from 1,680 just 4 years ago to 2,886 in 2012.
Top Japanese Stocks To Invest In Right Now: Sierra Wireless Inc. (SWIR)
Sierra Wireless, Inc., together with its subsidiaries, provides cellular wireless solutions to the machine-to-machine (M2M) and connected device markets in North America, Europe, and the Asia Pacific. The company operates through two segments, Mobile Computing and Machine-to-Machine. It offers AirPrime embedded wireless modules, which are used to wirelessly enable various products and solutions by original equipment manufacturers (OEMs); and AirLink intelligent gateways that are rugged and industrial-grade wireless terminals for M2M and mobile applications to public safety, transportation, field service, energy, industrial, and financial organizations. The company�s AirVantage M2M cloud platform provides secure, scalable, and device-to-cloud infrastructure for M2M applications. It also provides professional services to OEM customers during their product development and launch process. The company offers its products to consumer electronics, networking equipment, automotiv e, energy, security, sales and payment, industrial control and monitoring, fleet management, field service, and healthcare industries. It sells its products and solutions through various indirect channels, such as OEMs, wireless operators, distributors, and value-added resellers. Sierra Wireless, Inc. was founded in 1993 and is headquartered in Richmond, Canada.
Advisors' Opinion:- [By John Udovich]
Small cap machine-to-machine (M2M) stock Elecsys Corp (NASDAQ: ESYS) jumped 8.99% yesterday and is up 254% over the past year, meaning it might be time to take a closer look at the stock and its performance verses other small cap M2M stocks like Digi International Inc (NASDAQ: DGII), Numerex Corp (NASDAQ: NMRX) and Sierra Wireless, Inc (NASDAQ: SWIR). First of all though, I should mention that machine-to-machine (M2M) broadly refers to technologies that allow both wireless and wired systems to communicate with other devices of the same type and this can be through any type of technology ranging from instruments to networks to applications that create connections between devices.
- [By Chris Neiger]
We've already seen evidence of this. Last year, big IoT players�Intel (NASDAQ: INTC ) , General Electric (NYSE: GE ) , and Sierra Wireless (NASDAQ: SWIR ) all introduced or expanded their own Internet of Things platforms for managing embedded connections. General Electric opened the Predix platform to a small number of companies, and is making the software available to companies of all sizes in 2015. The company expects to generate $5 billion in revenue from Predix over the next two years.
No comments:
Post a Comment